- Home
- NXU vs TLPH Comparison
NXU vs TLPH Comparison
Compare NXU & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXU
- TLPH
- Stock Information
- Founded
- NXU 2016
- TLPH 2005
- Country
- NXU United States
- TLPH United States
- Employees
- NXU N/A
- TLPH N/A
- Industry
- NXU Automotive Aftermarket
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- NXU Consumer Discretionary
- TLPH Health Care
- Exchange
- NXU Nasdaq
- TLPH Nasdaq
- Market Cap
- NXU 14.3M
- TLPH 12.7M
- IPO Year
- NXU 2022
- TLPH 2011
- Fundamental
- Price
- NXU $0.55
- TLPH $0.67
- Analyst Decision
- NXU
- TLPH Strong Buy
- Analyst Count
- NXU 0
- TLPH 2
- Target Price
- NXU N/A
- TLPH $4.50
- AVG Volume (30 Days)
- NXU 35.2M
- TLPH 112.7K
- Earning Date
- NXU 11-13-2024
- TLPH 03-05-2025
- Dividend Yield
- NXU N/A
- TLPH N/A
- EPS Growth
- NXU N/A
- TLPH N/A
- EPS
- NXU N/A
- TLPH N/A
- Revenue
- NXU $396,000.00
- TLPH $281,000.00
- Revenue This Year
- NXU N/A
- TLPH N/A
- Revenue Next Year
- NXU N/A
- TLPH N/A
- P/E Ratio
- NXU N/A
- TLPH N/A
- Revenue Growth
- NXU 238.46
- TLPH N/A
- 52 Week Low
- NXU $0.21
- TLPH $0.50
- 52 Week High
- NXU $2.25
- TLPH $1.61
- Technical
- Relative Strength Index (RSI)
- NXU 49.26
- TLPH 55.43
- Support Level
- NXU $0.52
- TLPH $0.55
- Resistance Level
- NXU $0.74
- TLPH $0.64
- Average True Range (ATR)
- NXU 0.35
- TLPH 0.06
- MACD
- NXU -0.04
- TLPH 0.01
- Stochastic Oscillator
- NXU 15.63
- TLPH 94.06
About NXU Nxu Inc.
Nxu Inc is a technology company developing next-generation electric vehicle (EV) charging, battery, and vehicle technologies for mobility customers. Its technology company building energy and infrastructure solutions for consumers and businesses. Its NxuOne charging technology provides repeatable, consistent power delivery, designed to meet the needs of today's electric vehicles as well as those developed in the future.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.